Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MAGENTA THERAPEUTICS, INC.

(MGTA)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Magenta Therapeutics : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study in Q4

09/15/2021 | 09:15am EDT


ę MT Newswires 2021
All news about MAGENTA THERAPEUTICS, INC.
10/07PRESS RELEASE : Heidelberg Pharma AG: Interim Management Statement on the First Nine Month..
DJ
10/04MAGENTA THERAPEUTICS : Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
BU
10/04Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
CI
09/21MAGENTA THERAPEUTICS : to Participate in 2021 Cantor Virtual Global Healthcare Conference
BU
09/20Top Premarket Decliners
MT
09/15MAGENTA THERAPEUTICS : Gets FDA Clearance for Leukemia Drug Trial, Plans Phase 1/2 Study i..
MT
09/15Magenta Therapeutics Gets IND Clearance for MGTA-117
DJ
09/15MAGENTA THERAPEUTICS : Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical..
BU
09/15Magenta Therapeutics, Inc. Announces That Its Investigational New Drug Application for ..
CI
09/09TSCAN THERAPEUTICS : Names Zoran Zdraveski as Chief Legal Officer
MT
More news
Analyst Recommendations on MAGENTA THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -73,2 M - -
Net cash 2021 158 M - -
P/E ratio 2021 -5,01x
Yield 2021 -
Capitalization 391 M 391 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 78
Free-Float 91,8%
Chart MAGENTA THERAPEUTICS, INC.
Duration : Period :
Magenta Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MAGENTA THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,73 $
Average target price 15,71 $
Spread / Average Target 133%
EPS Revisions
Managers and Directors
Jason Gardner President, Chief Executive Officer & Director
Stephen Frank Mahoney COO, CFO, Treasurer & Chief Accounting Officer
Alison Francis Lawton Chairman
Lisa M. Olson Chief Scientific Officer & Head-Research
David Nichols Chief Technical Officer
Sector and Competitors
1st jan.Capi. (M$)
MAGENTA THERAPEUTICS, INC.-14.16%391
GILEAD SCIENCES, INC.16.08%84 795
WUXI APPTEC CO., LTD.29.45%66 184
BIONTECH SE203.83%59 820
REGENERON PHARMACEUTICALS14.52%57 519
VERTEX PHARMACEUTICALS-23.09%47 156